SEC I	Form 4
-------	--------

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287								
Estimated average burden								
0.5								

1. Title of Security	(instr. 3)		Date	Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8) Code		4. Securities Disposed Of Amount	(A) (Instr.	(A) or 3, 4 and 5) Price	5. Amount of Securities Beneficially Owned Follow Reported Transaction(s (Instr. 3 and 4	wing s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1 Title of Coouvity	(Instr 2)	Table I - Nor			•	,	Disp			-			6 Ownorchin	7. Nature of
(City)	(State)	(Zip)									Person			
(Street) SAN DIEGO	CA	92130								X	,			
			4.	. If Ame	endment, Date of C	Driginal	-iled (Month/Day/Ye	ar)	6. Indiv Line)	vidual or Joint/	/Group	Filing (Check A	plicable
NEUROCRINE 12790 EL CAM		, INC.						-yy			rie	sidem		
(Last)	(First)	f Reporting Person* 2. Issuer Name /IN CHARLES 2. Issuer Name First) (Middle) OSCIENCES, INC. 3. Date of Earli O REAL 4. If Amendment CA 92130 State) (Zip) Table I - Non-Derivative Securit tr. 3) 2. Transaction Date (Month/Day/Year) 2A. De Execurit		of Earliest Transac	onth/D	av/Year)	X	Officer (give below)		Other below	(specify)			
1. Name and Address of Reporting Person* GORMAN KEVIN CHARLES					r Name and Ticker ROCRINE B			ationship of Re k all applicable Director	eporting Person(s) to Issuer e) 10% Owner					
Instruction 1(b).	continue. See				t to Section 16(a) c tion 30(h) of the Inv					4		nours	per response:	0.5

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number Derivativ Securitie Acquired or Dispos of (D) (Ins 3, 4 and 5	e s (A) sed str.	6. Date Exerc Expiration Da (Month/Day/\	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Expiration Exercisable Date		Title	Amount or Number of Shares				
Stock Option ⁽¹⁾	\$5.12	02/27/2008		A		45,000		02/27/2009	02/27/2015	Common Stock	45,000	\$5.12	45,000	D	
Restricted Stock Unit	(2)	02/27/2008		A		125,000		(3)	(3)	Common Stock	125,000	\$ <mark>0</mark>	125,000	D	

Explanation of Responses:

1. Represents option of which 1/3 of the shares underlying the option becomes vested and exercisable on February 27, 2009, February 27, 2010 and February 27, 2011, respectively.

2. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock.

3. The restricted stock units will vest annually at 1/3 of the units vesting on March 27, 2009, February 27, 2010, and February 27, 2011, respectively.

Remarks:

<u>Margaret E. Valeur-Jensen, By</u> <u>Power of Attorney</u> <u>0</u>

02/29/2008

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.